[go: up one dir, main page]

MX2018002631A - Inhibidores de molecula pequeña de dyrkia y usos de los mismos. - Google Patents

Inhibidores de molecula pequeña de dyrkia y usos de los mismos.

Info

Publication number
MX2018002631A
MX2018002631A MX2018002631A MX2018002631A MX2018002631A MX 2018002631 A MX2018002631 A MX 2018002631A MX 2018002631 A MX2018002631 A MX 2018002631A MX 2018002631 A MX2018002631 A MX 2018002631A MX 2018002631 A MX2018002631 A MX 2018002631A
Authority
MX
Mexico
Prior art keywords
dyrk1a
small molecule
molecule inhibitors
diseases
inhibitors
Prior art date
Application number
MX2018002631A
Other languages
English (en)
Inventor
SHAW Yeng-jeng
Dunckley Travis
Hulme Christopher
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of MX2018002631A publication Critical patent/MX2018002631A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención está relacionada al campo de la química medicinal, la invención se refiere a una nueva clase de moléculas pequeñas que tienen una estructura de bencimidazol o imidazopiridina que funcionan como inhibidores de DYRKIA, y su uso como productos terapéuticos para el tratamiento de enfermedad de Alzheimer, síndrome de Down, glioblastoma, enfermedades autoinmunitarias, trastornos inflamatorios (por ejemplo, inflamación de vías aéreas) y otras enfermedades.
MX2018002631A 2015-09-03 2016-09-02 Inhibidores de molecula pequeña de dyrkia y usos de los mismos. MX2018002631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562213904P 2015-09-03 2015-09-03
PCT/US2016/050198 WO2017040993A1 (en) 2015-09-03 2016-09-02 Small molecule inhibitors of dyrk1a and uses thereof

Publications (1)

Publication Number Publication Date
MX2018002631A true MX2018002631A (es) 2019-02-07

Family

ID=58188489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002631A MX2018002631A (es) 2015-09-03 2016-09-02 Inhibidores de molecula pequeña de dyrkia y usos de los mismos.

Country Status (7)

Country Link
US (1) US10730842B2 (es)
EP (1) EP3344039A4 (es)
JP (1) JP2018526452A (es)
AU (1) AU2016315881B2 (es)
CA (1) CA2997556C (es)
MX (1) MX2018002631A (es)
WO (1) WO2017040993A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
KR102700664B1 (ko) * 2017-08-07 2024-08-29 조인트 스탁 컴퍼니 “바이오케드” Cdk8/19 저해제로서 새로운 헤테로사이클릭 화합물
RU2739489C2 (ru) * 2018-03-06 2020-12-24 Закрытое Акционерное Общество "Биокад" Новые гетероциклические соединения как ингибиторы CDK8/19
US11547712B2 (en) 2017-11-20 2023-01-10 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019105886A1 (en) * 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US12054483B2 (en) * 2018-09-28 2024-08-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
CN113164475A (zh) * 2018-11-19 2021-07-23 达纳-法伯癌症研究公司 Dyrk1a的大环抑制剂
CN113508111A (zh) * 2018-12-31 2021-10-15 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
AU2019418800A1 (en) * 2018-12-31 2021-07-01 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
GB201907616D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
EP3983391A4 (en) * 2019-06-12 2023-06-28 The Wistar Institute Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
WO2021096314A1 (ko) * 2019-11-15 2021-05-20 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
CN115768757B (zh) * 2019-12-19 2025-07-11 美利坚合众国,由健康及人类服务部部长代表 Cd206调节剂及其用途和制备方法
WO2022051291A2 (en) * 2020-09-02 2022-03-10 Ankh Life Sciences Limited Inhibition of dyrk1a kinase
CA3229864A1 (en) * 2021-09-13 2023-03-16 Provention Bio, Inc. Methods and compositions comprising anti-cd3 antibodies and dyrk1a inhibitors for treating diabetes
UY39979A (es) * 2021-10-12 2023-04-14 Biosplice Therapeutics Inc Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas
US20250066349A1 (en) * 2021-12-10 2025-02-27 Prothena Biosciences Limited Cyclic compounds and their use for the treatment of neurological disorders
WO2023107722A1 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Compounds for use in treating neurological disorders
AU2023371945A1 (en) * 2022-11-03 2025-05-22 Biosplice Therapeutics, Inc. 4-aminopyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
WO2024126404A1 (en) * 2022-12-14 2024-06-20 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
EP4434972A1 (en) * 2023-03-22 2024-09-25 Eberhard-Karls-Universität Tübingen Atm kinase inhibitors
WO2024249488A2 (en) * 2023-05-30 2024-12-05 Beth Israel Deaconess Medical Center, Inc. Inhibitors of dyrk1a
WO2024259121A1 (en) * 2023-06-14 2024-12-19 Prothena Biosciences Limited Bicyclic heteroaromatic compounds for treating neurological disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1076582A (en) * 1975-10-28 1980-04-29 Charles J. Paget Antiviral thiazolinyl or thiazinyl ketobenzimidazoles
US4331671A (en) 1981-01-09 1982-05-25 Sterling Drug Inc. 5-(Pyridinyl)-1H-benzimidazoles and 1-hydroxy-6-(pyridinyl)-1H-benzimidazoles and their cardiotonic use
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
TWI306859B (en) * 2000-04-28 2009-03-01 Acadia Pharm Inc Muscarinic agonists
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
PL366690A1 (en) * 2004-03-29 2005-10-03 Fundacja Rozwoju Diagnostyki I Terapii New derivatives of 4,5,6,7-tetrabromobenzimidazole and method for their obtaining
DOP2006000051A (es) * 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
CA2665214A1 (en) * 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
TW201006839A (en) 2008-07-18 2010-02-16 Sanofi Aventis Novel imidazo[1,2-a]pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors
MX2011006509A (es) 2008-12-19 2011-10-19 Genentech Inc Compuestos heterociclicos y métodos de uso.
PE20170003A1 (es) * 2009-08-17 2017-03-15 Intellikine Llc Compuestos heterociclicos y usos de los mismos
US20110230481A2 (en) * 2009-11-12 2011-09-22 Selvita S.A. Derivatives of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition comprising the same, a method of using the same, a method for modulating or regulating serine/threonine kinases, and serine/threonine kinases modulating agent
WO2012174312A2 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
DK2744797T3 (en) 2011-08-19 2015-10-19 Diaxonhit Dyrk1-inhibitors and uses thereof
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
EP2903980B1 (en) * 2012-10-01 2017-07-19 F. Hoffmann-La Roche AG Benzimidazoles as cns active agents
GB201223265D0 (en) * 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
CA2906542A1 (en) * 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
DE102014009011A1 (de) 2013-06-18 2014-12-18 4Sc Discovery Gmbh Verfahren zum Inhibieren von DYRK1B
CN104447567B (zh) 2014-11-02 2016-06-29 湖南华腾制药有限公司 一种1位取代苯并咪唑衍生物的制备方法

Also Published As

Publication number Publication date
US10730842B2 (en) 2020-08-04
JP2018526452A (ja) 2018-09-13
WO2017040993A1 (en) 2017-03-09
EP3344039A1 (en) 2018-07-11
EP3344039A4 (en) 2019-08-28
CA2997556C (en) 2020-12-22
AU2016315881B2 (en) 2019-09-19
US20190062284A1 (en) 2019-02-28
AU2016315881A1 (en) 2018-03-29
WO2017040993A4 (en) 2017-05-26
CA2997556A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
MX2018002631A (es) Inhibidores de molecula pequeña de dyrkia y usos de los mismos.
SA518391624B1 (ar) Ror- منظمات جاما
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
EA201792047A1 (ru) Новые соединения
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
CY1119615T1 (el) Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης
MX2020004506A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
JOP20190001A1 (ar) عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA201700042A1 (ru) Соединения имидазопиридазина
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
EA201391440A1 (ru) Производные пиразолопиримидина
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
WO2015082590A3 (en) Bis-mmf derivatives
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
MX2017003016A (es) Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.
MX378175B (es) Novedosos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.